ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,602Medicare Part D Prescriptions Filled, Including Refills

Rank: 122 out of 761

$455K Total Retail Price of All Prescriptions

Rank: 160 out of 761

507 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 507 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

14% of this provider’s 507 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

3% of this provider’s 8,131 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LISINOPRIL 488 386 1 1
AMLODIPINE BESYLATE 354 302 2 6
FUROSEMIDE 307 281 3 7
LEVOTHYROXINE SODIUM 280 267 4 3
SIMVASTATIN 274 234 5 2
ATENOLOL 244 227 6 8
HYDROCODONE-ACETAMINOPHEN 235 176 S3 7 5
OMEPRAZOLE 220 177 8 4
WARFARIN SODIUM 208 181 9 9
METOPROLOL TARTRATE 202 171 10 14
LOVASTATIN 197 167 11 17
CITALOPRAM HBR 171 158 12 19
POTASSIUM CHLORIDE 167 153 13 18
HYDROCHLOROTHIAZIDE 165 140 14 11
METFORMIN HCL 165 125 14 10
ATORVASTATIN CALCIUM 162 143 16 12
OXYCODONE HCL 147 119 S2 17 24
GABAPENTIN 145 124 18 15
ZOLPIDEM TARTRATE 121 88 19 22
OXYBUTYNIN CHLORIDE 111 86 20 85
PROAIR HFA 106 92 21 32
ALENDRONATE SODIUM 106 101 21 21
METOPROLOL SUCCINATE 104 95 23 16
LOSARTAN POTASSIUM 99 99 24 13
SERTRALINE HCL 95 80 25 25
CYCLOBENZAPRINE HCL 89 56 R 26 51
DONEPEZIL HCL 88 88 27 33
PANTOPRAZOLE SODIUM 85 80 28 40
TAMSULOSIN HCL 83 67 29 27
DIGOXIN 83 76 29 43
TRAMADOL HCL 81 66 31 34
OXYCODONE-ACETAMINOPHEN 81 59 S2 31 49
NAMENDA 76 76 33 59
PAROXETINE HCL 74 52 34 47
ADVAIR DISKUS 74 72 34 37
FELODIPINE ER 73 55 36 108
TRAZODONE HCL 71 61 37 23
FLUTICASONE PROPIONATE 69 59 38 29
ACETAMINOPHEN-CODEINE 61 57 S3 39 118
ALLOPURINOL 60 58 40 28
CRESTOR 59 50 41 36
LANTUS 58 34 42 41
SULFAMETHOXAZOLE-TRIMETHOPRIM 54 44 43 117
MIRTAZAPINE 53 53 44 50
TRIAMCINOLONE ACETONIDE 52 40 45 84
SPIRONOLACTONE 50 43 46 45
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 18, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.